Clinical Trial Goal
To find out if the combination of mosunetuzumab and tazemetostat is safe and works well to treat follicular lymphoma that has not yet been treated
You may be able to join this trial if you:
- Are 18 years old or older
- Have follicular lymphoma (grades 1-3a) and have received little to no treatment
- Do not have Grade 3b follicular lymphoma
- Do not have lymphoma in your brain or spinal cord
- Have not had an allogeneic (cells from a donor) blood or marrow transplant (BMT)
- Agree to have other standard tests done to see if you can be in the clinical trial
Trial Details
Mosunetuzumab is a T-cell engaging bispecific antibody that target CD20 and CD3 on certain cells.
Tazemetostat is a small molecule inhibitor that blocks EZH2 in certain cells.
You’ll get treatment in cycles that last 1 month. In each cycle, you'll get:
Tazemetostat is a small molecule inhibitor that blocks EZH2 in certain cells.
You’ll get treatment in cycles that last 1 month. In each cycle, you'll get:
- Mosunetuzumab – Given as a shot under your skin 1 time
- Tazemetostat – A pill that you take by mouth 2 times each day
You may continue treatment for as long as the clinical trial doctors think it’s best for your health. You'll have scans to see how well the treatment is working. The clinical trial doctors will check your health for up to 10 years.
The Food and Drug Administration (FDA) has approved all of the drugs used in this trial. Using them together in this way to treat follicular lymphoma that has not yet been treated, is new and unproven.
Contacts
Tejasvi Kaur Sahni, 646-962-9337, tks4001@med.cornell.edu
Brittany Hobbie, brh4008@med.cornell.edu
Locations
Weill Cornell Medicine/NewYork-Presbyterian HospitalRECRUITING
New York, New York
Contacts:
- Tejasvi Kaur Sahni, tks4001@med.cornell.edu
- Brittany Hobbie, brh4008@med.cornell.edu
Sponsors
collaborator: Epizyme, Inc., collaborator: Genentech, Inc., lead: Weill Medical College of Cornell University
